Loading...

We've got a brand new version of Simply Wall St! Try it out

Happiness Biotech Group

Nasdaq:HAPP
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HAPP
Nasdaq
$114M
Market Cap
  1. Home
  2. US
  3. Household
Company description

Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplements products made of Lucidum spore powder and others in the People’s Republic of China. The last earnings update was 78 days ago. More info.


Add to Portfolio Compare Print
HAPP Share Price and Events
7 Day Returns
-3.6%
NasdaqCM:HAPP
2.2%
US Personal Products
0.3%
US Market
1 Year Returns
-
NasdaqCM:HAPP
20.5%
US Personal Products
12.5%
US Market
HAPP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Happiness Biotech Group (HAPP) -3.6% - - - - -
US Personal Products 2.2% -1.1% 5.5% 20.5% 54.3% 59.2%
US Market 0.3% 4.1% 5.6% 12.5% 39.4% 44.7%
1 Year Return vs Industry and Market
  • No trading data on HAPP.
  • No trading data on HAPP.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Happiness Biotech Group's competitors could be found in our database.

Value

 Is Happiness Biotech Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Happiness Biotech Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Happiness Biotech Group.

NasdaqCM:HAPP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:HAPP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.68
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.68 (1 + (1- 25%) (0.91%))
0.789
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for NasdaqCM:HAPP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Happiness Biotech Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqCM:HAPP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.5%)
2020 5.00 Est @ -16.65% 4.65
2021 4.45 Est @ -10.84% 3.86
2022 4.15 Est @ -6.77% 3.34
2023 3.99 Est @ -3.92% 2.99
2024 3.91 Est @ -1.92% 2.73
2025 3.89 Est @ -0.53% 2.52
2026 3.91 Est @ 0.45% 2.36
2027 3.96 Est @ 1.13% 2.22
2028 4.02 Est @ 1.61% 2.10
2029 4.10 Est @ 1.95% 1.99
Present value of next 10 years cash flows $28.00
NasdaqCM:HAPP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $4.10 × (1 + 2.73%) ÷ (7.5% – 2.73%)
$88.28
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $88.28 ÷ (1 + 7.5%)10
$42.84
NasdaqCM:HAPP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $28.00 + $42.84
$70.84
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $70.84 / 25.00
$2.83
NasdaqCM:HAPP Discount to Share Price
Calculation Result
Value per share (USD) From above. $2.83
Current discount Discount to share price of $4.57
= -1 x ($4.57 - $2.83) / $2.83
-61.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Happiness Biotech Group is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Happiness Biotech Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Happiness Biotech Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:HAPP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.81
NasdaqCM:HAPP Share Price ** NasdaqCM (2019-11-12) in USD $4.57
United States of America Personal Products Industry PE Ratio Median Figure of 21 Publicly-Listed Personal Products Companies 17.08x
United States of America Market PE Ratio Median Figure of 2,922 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Happiness Biotech Group.

NasdaqCM:HAPP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:HAPP Share Price ÷ EPS (both in USD)

= 4.57 ÷ 0.81

5.61x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Happiness Biotech Group is good value based on earnings compared to the US Personal Products industry average.
  • Happiness Biotech Group is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Happiness Biotech Group's expected growth come at a high price?
Raw Data
NasdaqCM:HAPP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 5.61x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
2.8%per year
United States of America Personal Products Industry PEG Ratio Median Figure of 6 Publicly-Listed Personal Products Companies 2.56x
United States of America Market PEG Ratio Median Figure of 2,023 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Happiness Biotech Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Happiness Biotech Group's assets?
Raw Data
NasdaqCM:HAPP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.65
NasdaqCM:HAPP Share Price * NasdaqCM (2019-11-12) in USD $4.57
United States of America Personal Products Industry PB Ratio Median Figure of 43 Publicly-Listed Personal Products Companies 2.65x
United States of America Market PB Ratio Median Figure of 5,066 Publicly-Listed Companies 1.74x
NasdaqCM:HAPP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:HAPP Share Price ÷ Book Value per Share (both in USD)

= 4.57 ÷ 2.65

1.73x

* Primary Listing of Happiness Biotech Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Happiness Biotech Group is good value based on assets compared to the US Personal Products industry average.
X
Value checks
We assess Happiness Biotech Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Happiness Biotech Group has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Happiness Biotech Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Happiness Biotech Group, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Happiness Biotech Group expected to grow at an attractive rate?
  • Happiness Biotech Group's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Happiness Biotech Group's earnings growth is positive but not above the United States of America market average.
  • Unable to compare Happiness Biotech Group's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:HAPP Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:HAPP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 2.8%
United States of America Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 17.7%
United States of America Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 6.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:HAPP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:HAPP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 64 7 19
2018-12-31 64 8 18
2018-09-30 64 9 18
2018-06-30 63 11 18
2018-03-31 61 13 17
2017-03-31 53 11 15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Happiness Biotech Group's earnings are expected to grow by 2.8% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Happiness Biotech Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:HAPP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (7 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Happiness Biotech Group Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:HAPP Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.81
2018-12-31 0.79
2018-09-30 0.18
2018-06-30 0.18
2018-03-31 0.76
2017-03-31 0.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Happiness Biotech Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Happiness Biotech Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Happiness Biotech Group has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Happiness Biotech Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Happiness Biotech Group's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient data to establish if Happiness Biotech Group's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Happiness Biotech Group's 1-year earnings growth to the 5-year average due to insufficient past data.
  • Happiness Biotech Group's earnings growth has not exceeded the US Personal Products industry average in the past year (7% vs 19.9%).
Earnings and Revenue History
Happiness Biotech Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Happiness Biotech Group Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:HAPP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 63.94 18.72 8.24 2.16
2018-12-31 64.00 18.24 8.38 2.15
2018-09-30 64.05 17.76 8.51 2.15
2018-06-30 62.77 17.62 7.88 2.00
2018-03-31 61.50 17.49 7.25 1.86
2017-03-31 53.00 14.52 6.96 1.66

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Happiness Biotech Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Happiness Biotech Group used its assets more efficiently than the US Personal Products industry average last year based on Return on Assets.
  • Unable to establish if Happiness Biotech Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess Happiness Biotech Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Happiness Biotech Group has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Happiness Biotech Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Happiness Biotech Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Happiness Biotech Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Happiness Biotech Group has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Happiness Biotech Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 52.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Happiness Biotech Group Company Filings, last reported 7 months ago.

NasdaqCM:HAPP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 60.92 1.04 14.80
2018-12-31 60.92 1.04 14.80
2018-09-30 49.81 1.37 13.39
2018-06-30 49.81 1.37 13.39
2018-03-31 44.55 1.49 8.88
2017-03-31 23.31 1.85 4.27
  • Happiness Biotech Group's level of debt (1.7%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Happiness Biotech Group's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (629.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 526.2x coverage).
X
Financial health checks
We assess Happiness Biotech Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Happiness Biotech Group has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Happiness Biotech Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Happiness Biotech Group dividends.
If you bought $2,000 of Happiness Biotech Group shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Happiness Biotech Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Happiness Biotech Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:HAPP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1948 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Happiness Biotech Group has not reported any payouts.
  • Unable to verify if Happiness Biotech Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Happiness Biotech Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Happiness Biotech Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Happiness Biotech Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Happiness Biotech Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Happiness Biotech Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Happiness Biotech Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Xuezhu Wang
AGE 35
TENURE AS CEO 1.3 years
CEO Bio

Mr. Xuezhu Wang has been Chief Executive Officer and Executive Director of Happiness Biotech Group Limited since August 28, 2018. He has been the Chief Executive Officer of Fujian Happiness, Chinese subsidiary of Happiness Biotech Group Ltd. since 2015. As the CEO of Fujian Happiness, he was responsible for procurement and formulating a cost-effective strategy for purchasing goods and services. Mr. Wang studied the courses of Executive MBA in Peking University in 2013 and obtained an MBA degree from University of Wales in 2015. Mr. Wang received his college degree from Minjiang University in 2006.

CEO Compensation
  • Insufficient data for Xuezhu to compare compensation growth.
  • Insufficient data for Xuezhu to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team

Xuezhu Wang

TITLE
CEO & Director
AGE
35
TENURE
1.3 yrs

Jiong Bian

TITLE
Chief Financial Officer
AGE
51
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Happiness Biotech Group board of directors in years:

1.3
Average Tenure
61
Average Age
  • The average tenure for the Happiness Biotech Group board of directors is less than 3 years, this suggests a new board.
Board of Directors

Xianfu Wang

TITLE
Chairman
AGE
61
TENURE
1.3 yrs

Xuezhu Wang

TITLE
CEO & Director
AGE
35
TENURE
1.3 yrs

John Levy

TITLE
Independent Director
AGE
63
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Happiness Biotech Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Happiness Biotech Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplements products made of Lucidum spore powder and others in the People’s Republic of China. It also offers edible fungi. The company was founded in 2004 and is based in Nanping, the People’s Republic of China.

Details
Name: Happiness Biotech Group Limited
HAPP
Exchange: NasdaqCM
Founded: 2004
$114,250,000
25,000,000
Website: http://www.fjxfl.com
Address: Happiness Biotech Group Limited
No. 11, Dongjiao East Road,
Shuangxi,
Nanping,
Fujian Province, 353200,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM HAPP Ordinary Shares Nasdaq Capital Market US USD 25. Oct 2019
Number of employees
Current staff
Staff numbers
0
Happiness Biotech Group employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/13 00:41
End of day share price update: 2019/11/12 00:00
Last earnings filing: 2019/08/27
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.